On February 4, 2019 Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) constructs, reported that its CEO, Dr. David Giljohann, will present at the Immuno-Oncology 360° Conference (IO360°) being held February 6-8, 2019 at the Crowne Plaza Times Square in New York City (Press release, Exicure, FEB 4, 2019, View Source [SID1234533037]). Dr. Giljohann’s presentation titled "Innate Immune System Activation with Spherical Nucleic Acids" will occur on Thursday, February 7, 2019 at 4:30 pm EST during the Translational Science & Emerging Biomarkers Part II track.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On February 4, 2019 INmune Bio, Inc. ("INmune" or the "Company"), an immunotherapy company focused on developing therapies that harness the patient’s innate immune system to fight disease, reported that the Company’s common stock is expected to commence trading on The Nasdaq Capital Market, on Monday, February 4, 2019 under the ticker symbol "INMB" (Press release, INmune Bio, FEB 4, 2019, View Source [SID1234533090]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On February 1, 2019, INmune closed its initial public offering ("IPO") of 1,020,560 shares of its common stock at of $8.00 per share for a total of $8,166,560 in gross proceeds before placement agent fees and offering expenses.

Univest Securities, LLC served as the lead placement agent for the IPO. WallachBeth Capital, LLC and WestPark Capital, Inc. were co-placement agents.

A registration statement relating to this U.S. offering was filed with the Securities and Exchange Commission ("SEC") and was declared effective by the SEC as of December 19, 2018. The offering of the securities was made only by means of a prospectus, forming a part of the registration statement. Copies of the final prospectus relating to the U.S. offering may be obtained from Univest Securities, LLC. 375 Park Avenue Unit 1502, New York, NY 10152, by telephone at +1 212 343 8888 or email at [email protected]. In addition, a copy of the prospectus relating to the offering may be obtained via the SEC’s website at www.sec.gov.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On February 4, 2019 Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing a new class of potent and selective miniature drug conjugates (Pentarins) for the treatment of patients with a wide range of solid tumors, reported that Drew Fromkin, President and Chief Executive Officer, will present at the 2019 BIO CEO & Investor Conference, occurring February 11-12, 2019 at the New York Marriot Marquis (Press release, Tarveda Therapeutics, FEB 4, 2019, View Source [SID1234533038]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will take place at 2:15pm Eastern Time on Monday, February 11 in the Gramercy room.

In the presentation, Mr. Fromkin will provide an overview of the Company’s two clinical programs including PEN-221, which is currently in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) positive neuroendocrine tumors and PEN-866, the first miniature drug conjugate from Tarveda’s HSP90 binding conjugate platform, which is being developed for the treatment of patients with solid tumors including but not limited to small cell lung cancer, pancreatic cancer and sarcomas.

On February 4, 2019 Syntrix Pharmaceuticals reported that it has been awarded a three-year grant worth $3.4 million from the National Heart Lung and Blood Institute of the National Institutes of Health to assess its investigational CXCR1/2 inhibitor SX-682 in patients with low- and high-risk myelodysplastic syndrome (MDS) who had progression or were intolerant to prior therapy (Press release, Syntrix, FEB 4, 2019, View Source [SID1234553882]). The phase 1/2 clinical trial will be carried out in collaboration with researchers at the Moffitt Cancer Center led by Dr. Rami Kamrokji.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Patients with low-risk MDS have an expected median survival measured in years, but suffer from hematologic deficits and related symptoms that lead to transfusion dependence," said Syntrix’s President John Zebala. "Patients with high-risk MDS have debilitating cytopenias and borderline leukemia, and can have expected survival measured in months."

Only three drugs have received regulatory approval for MDS treatment, all with suboptimal response rates (<50%) and of limited durability (1-2 years). Once these agents fail in patients, there is no second-line treatment. Prognosis after failure is dismal, with median survival estimated at <6 months for higher-risk patients, and <18 months for lower-risk patients.

The Phase 1/2 clinical trial of SX-682 builds on groundbreaking discoveries by investigators at the Moffitt Cancer Center and the Albert Einstein College of Medicine who showed CXCR1/2 is pivotal in MDS and that its inhibition is a therapeutic strategy against the disease.

This Phase 1/2 trial in MDS patients will test the hypothesis that targeting CXCR1/2 with SX-682 will be efficacious in the disease by eliminating the MDS stem cells and bone marrow MDSCs. The FDA approved the protocol for the study in an IND sponsored by Syntrix.

ABOUT SX-682: SX-682 is a clinical-stage oral allosteric small-molecule inhibitor of CXCR1 and CXCR2 (CXCR1/2). Inhibiting both human receptors is believed essential. CXCR1/2 are a combined "master switch" of the immunosuppressive tumor microenvironment. Clinical studies in melanoma, breast, ovarian, prostate and colon cancer have shown a direct correlation between serum levels of CXCR1/2 ligands and disease progression. SX-682 has been validated in all major solid tumor models, where it exhibits mono-agent anti-tumor activity, blocks metastasis, depletes immunosuppressive myeloid cells, activates tumor killing by effector cells, reverses chemo-resistance, and potently synergizes with anti-CTLA-4 and anti-PD1. SX-682 is also being evaluated in solid tumors supported by the National Cancer Institute.

On February 3, 2019 GeneQuantum Healthcare of Suzhou and MITRO Biotech of Nanjing reported that signed the "Strategic Cooperation Agreement on Next Generation Radionuclide Conjugates Development" in Nanjing. Dr. Gang Qin, President of GeneQuantum and Dr. Xinping Li, CEO of MITRO, attended the signing ceremony with their teams (Press release, GeneQuantum Healthcare, FEB 3, 2019, View Source [SID1234553991]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In pursuit of achieving mutually beneficial win-win cooperation, the two parties intend to integrate the leading bioconjugation platform of GeneQuantum and the unique advantages of MITRO in radiolabeling and molecular imaging technique to jointly develop next generation radionuclide conjugates for rapid and efficient companion diagnosis and precision target therapy on tumors.

"Since its establishment, GeneQuantum has been committed to building a differentiated innovation platform to solve the key challenges of the biopharmaceutical industry. Based on our proprietary ligase dependent conjugation technology (LDC), GeneQuantum has gradually established intelligent automatic conjugation system (iLDC) with concurrent fully integrated manufacturing process; combined with our comprehensive quality system which meets global standard, GeneQuantum can provide a holistic solution for the efficient development and manufacturing of any kinds of site-specific bioconjugates. MITRO, on the other hand, has a unique radionuclide production and labeling technology platform," said Dr. Gang Qin. "We are pleased to work with a distinctive and leading technology partner such as MITRO to develop next generation radionuclide conjugates for both diagnostic and therapeutic purposes, meeting the unmet clinical needs of cancer patients worldwide."

"MITRO focuses on the development and application of isotope labeling and molecular imaging technology, and is committed to establishing a biomedical innovation and transformation research platform, using the advanced isotope labeling and molecular imaging technology to develop new drugs," said Dr. Xinping Li. "We are glad to work with GeneQuantum Healthcare based on our mutual interest of advanced medicine. This cooperation will fully integrate the technical and resource advantages of GeneQuantum in site-specific bioconjugation and MITRO in isotope labeling and non-invasive molecular imaging technology. The collaboration will create an internationally competitive platform of radionuclide bioconjugates for medical use. This will contribute to the most efficient non-invasive diagnosis of cancer and precise targeted therapy, as well as a systemic solution of novel biomedical drug development."